Desmopressin in nocturnal enuresis.

Aladjem M, Wohl R, Boichis H, Orda S, Lotan D, Freedman S

Archives of disease in childhood1 Feb 1982Cited by 42 (Europe PMC)

PMID7039520PMCIDPMC1627511DOI10.1136/adc.57.2.137PepBankPUB-07039520

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In enuretic children, DDAVP significantly reduced wet nights from 18.7 ± 6.5 to 6.5 ± 9.2 per 30 days.
In plain wordsIn children with bedwetting, DDAVP reduced wet nights compared with before treatment.
Peptide
Desmopressin
Outcome
DecreaseWet nights per 30 days
Study
n = 15
Comparator
Before treatment
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated
Measurements
Wet nights
18.7 per 30 days
before treatment
Wet nights
6.5 per 30 days
DDAVP
Source sentences
Summary
The 15 children treated with DDAVP showed a significant reduction in the incidence of bed wetting--from 18.7 +/- 6.5 to 6.5 +/- 9.2 wet nights per 30 days.
1 context sentence(design, population, supporting numbers)
Summary · context
The response of desamino-D-arginine vasopressin (DDAVP) was investigated in 32 enuretic children in a double-blind clinical study.
Report a problemFND-0703952001
02HumanNon-randomized trialEfficacy outcome
During DDAVP treatment, bedwetting stopped entirely in 6 children.
In plain wordsDuring DDAVP treatment, bedwetting stopped entirely in 6 children.
Peptide
Desmopressin
Outcome
Not applicableComplete cessation of bedwetting
Study
n = 15
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated
Measurements
Children with complete cessation of bedwetting
6 children
during DDAVP treatment
Source sentences
Summary
In 6 children bed wetting stopped entirely, in 6 there was a satisfactory response, and in 3 the response was marginal or there was none.
1 context sentence(design, population, supporting numbers)
Summary · context
The response of desamino-D-arginine vasopressin (DDAVP) was investigated in 32 enuretic children in a double-blind clinical study.
Report a problemFND-0703952002
03HumanNon-randomized trialEfficacy outcome
During DDAVP treatment, 6 children had a satisfactory response.
In plain wordsDuring DDAVP treatment, 6 children had a satisfactory response.
Peptide
Desmopressin
Outcome
Not applicableSatisfactory response
Study
n = 15
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated
Measurements
Children with satisfactory response
6 children
during DDAVP treatment
Source sentences
Summary
In 6 children bed wetting stopped entirely, in 6 there was a satisfactory response, and in 3 the response was marginal or there was none.
1 context sentence(design, population, supporting numbers)
Summary · context
The response of desamino-D-arginine vasopressin (DDAVP) was investigated in 32 enuretic children in a double-blind clinical study.
Report a problemFND-0703952003
04HumanNon-randomized trialEfficacy outcome
During DDAVP treatment, 3 children had marginal or no response.
In plain wordsDuring DDAVP treatment, 3 children had marginal or no response.
Peptide
Desmopressin
Outcome
Not applicableMarginal or absent response
Study
n = 15
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated
Measurements
Children with marginal or no response
3 children
during DDAVP treatment
Source sentences
Summary
In 6 children bed wetting stopped entirely, in 6 there was a satisfactory response, and in 3 the response was marginal or there was none.
1 context sentence(design, population, supporting numbers)
Summary · context
The response of desamino-D-arginine vasopressin (DDAVP) was investigated in 32 enuretic children in a double-blind clinical study.
Report a problemFND-0703952004
05HumanNon-randomized trialEfficacy outcome
After DDAVP withdrawal, most children returned to earlier bedwetting habits, with 15.7 ± 8.9 wet nights monthly.
In plain wordsAfter DDAVP stopped, most children returned to their earlier bedwetting habits.
Peptide
Desmopressin
Outcome
IncreaseBedwetting after withdrawal
Study
n = 15
Comparator
During DDAVP treatment
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated
Measurements
Wet nights
15.7 nights a month
after withdrawal
Source sentences
Summary
When DDAVP was stopped most children reverted to their earlier bedwetting habits (15.7 +/- 8.9 nights a month).
1 context sentence(design, population, supporting numbers)
Summary · context
The response of desamino-D-arginine vasopressin (DDAVP) was investigated in 32 enuretic children in a double-blind clinical study.
Report a problemFND-0703952005
06HumanNon-randomized trialEfficacy outcome
In enuretic children, DDAVP did not appreciably change morning urine osmolality.
In plain wordsIn children with bedwetting, DDAVP did not appreciably change morning urine concentration.
Peptide
Desmopressin
Outcome
No significant changeMorning urine osmolality
Study
n = 15
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
The administration of DDAVP was not associated with any appreciable change in morning urine osmolalities.
1 context sentence(design, population, supporting numbers)
Summary · context
The response of desamino-D-arginine vasopressin (DDAVP) was investigated in 32 enuretic children in a double-blind clinical study.
Report a problemFND-0703952007
07HumanNon-randomized trialSafety outcome
No adverse effects were noted during DDAVP treatment of enuretic children.
In plain wordsNo adverse effects were noted during DDAVP treatment of children with bedwetting.
Peptide
Desmopressin
Outcome
Not applicableAdverse effects
Study
n = 15
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated
Source sentences
Summary
No adverse effects were noted.
1 context sentence(design, population, supporting numbers)
Summary · context
The response of desamino-D-arginine vasopressin (DDAVP) was investigated in 32 enuretic children in a double-blind clinical study.
Report a problemFND-0703952008
08HumanNon-randomized trialEfficacy outcome
DDAVP response was significantly better in children older than 10 years than in younger children.
In plain wordsDDAVP worked better in children older than 10 years than in younger children.
Peptide
Desmopressin
Outcome
IncreaseResponse by age
Study
n: not reported in source
Comparator
Younger children
Outcome group
Urinary continence and bladder function · Kidney and urinary
Studied dose
Dose not stated
Source sentences
Summary
Response to DDAVP was significantly better in children aged more than 10 years (mean age for the entire group).
1 context sentence(design, population, supporting numbers)
Summary · context
The response of desamino-D-arginine vasopressin (DDAVP) was investigated in 32 enuretic children in a double-blind clinical study.
Report a problemFND-0703952006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.